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Review
 Just about every physician has seen a case like this and 
then may call his or her laboratory-based colleagues for as-
sistance.
 Mabel Throckmorton, 67 years old, was admitted for 
treatment of community-acquired pneumonia. After obtain-
ing cultures, two appropriate antibiotics were begun, but 
her respiratory status deteriorated to require intubation and 
ventilation. Two days later, as her pulmonary status began 
to improve, a routine (automated) CBC noted that her plate-
let count had dropped from 220,000/μL on admission to 
15,000/μL. Her leukocyte count had peaked at 22,000/μL 
and had now declined to 10,000/μL. Her hematocrit had de-
creased from 38% to 33%.  Her peripheral smear was unre-
markable except for the cytopenias. Her medications before 
admission included a diuretic, digoxin, and a statin for cho-
lesterol control. In addition to the antibiotics she was receiv-
ing, additional hospital medications included albuterol and 
omeprazole.
 The patient had a history of spontaneous intracranial 
hemorrhage 30 years previously, which resolved without 
permanent impairment, and chemotherapy and transfu-
sion for an aggressive lymphoma 10 years previously. Mul-
tiple transfusions coupled with five pregnancies resulted in 
the patient’s being broadly alloimmunized to HLAs, and she 
required difficult-to-find matched platelets for transfusion 
support during that chemotherapy.
 Is the sudden and dramatic thrombocytopenia related to 
the primary illness, previous disease reappearance, or some-
thing nosocomial? If a drug caused the platelet count drop, 
which one is the culprit? Because the infection appears to be 
under effective treatment, the patient’s physician will under-
standably be reluctant to change antibiotics at this juncture. 
However, given the patient’s previous history of intracra-
nial hemorrhage, considerable anxiety would accompany 
the dramatic appearance of thrombocytopenia, particularly 
when transfusion support would be difficult to obtain. How 
can the laboratory assist in the evaluation and treatment of 
this patient?
 The frequency of drug-induced thrombocytopenia is 
staggering. Although only 1 person in 100,000 encounters 
this annually in the United States,1 some medications such 
as trimethoprim-sulfamethoxazole or quinine/quinidine can 
increase this rate 1500-fold.2 Perhaps a quarter of all inten-
sive care patients exhibit thrombocytopenia as a result of 
drugs,3,4 and 6 percent of patients receiving the common an-
tibiotic gentamicin make drug-dependent platelet antibodies 
(DDPAs).5 Although heparin-induced thrombocytopenia (a 
unique form of drug-platelet interaction that will not be dis-
cussed here) is well known and often considered in the dif-
ferential diagnosis of thrombocytopenia,6 other drugs (given 
the frequency of their use) probably account for far more 
cases of drug-induced thrombocytopenia.
First Things First
 However, before laying the blame for all thrombocy-
topenia on medications, let us first make sure that the prob-
lem is not something else (Table 1). Is the patient’s plate-
let count really low? Some patients’ platelets agglutinate 
in EDTA,7 and some patients have autoantibodies against 
GPIIb/IIIa that display avidity in EDTA samples.8 In this 
case, the normal platelet count on admission makes these 
unlikely causes. Idiopathic autoimmune thrombocytopenia 
Table 1. Why is the patient thrombocytopenic?
Pseudothrombocytopenia
     EDTA-induced aggregation
     Glycoprotein autoantibodies avid only in EDTA
Production deficit
     Primary marrow failure
     Ineffective production, e.g., myelodysplasia
     Primary malignancy, e.g., leukemia
     Secondary malignancy (metastatic disease)
     Antineoplastic medications
Accelerated peripheral clearance
     Idiopathic thrombocytopenic purpura (ITP)
     Posttransfusion purpura
     Thrombotic thrombocytopenic purpura (TTP)
     Hemolytic uremic syndrome (HUS)
     HELLP: hemolytic anemia, elevated liver enzymes, low platelets*
     Disseminated intravascular coagulation (DIC)
     Massive hemorrhage
Drug-induced thrombocytopenia
     Heparin-induced thrombocytopenia/thrombosis
     Autoantibodies (ex: procainamide)
     Fabmurine antibodies (ex: abciximab)
     Hapten-induced antibodies (ex: penicillin, cephalosporins)
     Glycoprotein-complexing drug (ex: quinine)
     Autoantibody recognition of glycoprotein conformational change 
     (ex:fibans)
*A variant of preeclampsia.
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and the platelets or RBCs involved in the process are inno-
cent bystanders that are removed from circulation after ad-
sorbing or binding the complex onto their surface. However, 
most drugs are too small to provoke an immune response, 
and immune complexes of drug-immunoglobulin could not 
be demonstrated when sought. Furthermore, interactions of 
DDPAs with the cells that are removed from circulation are 
through binding with the antibodies’ (epitope-specific) Fab 
domains rather than the Fc domain,12,13 suggesting that the 
antibodies are interacting directly with the platelets in the 
presence of the drug.
 This theory has been supplanted by one involving (non-
covalent) interaction between the drug and a surface protein, 
leading to a change in the conformation of the protein that 
would allow naturally occurring antibodies to now interact 
with the protein with sufficient avidity to provoke removal 
of the cell.14,15 Most DDPAs appear to interact with GPIIb/
IIIa, which binds fibrinogen and other ligands, or GPIb/IX, 
the von Willebrand factor receptor, for reasons that are not 
currently well understood.16
 A form of this mechanism has been invoked to explain 
why first exposure to fibans can cause rapid and profound 
thrombocytopenia in a small proportion of patients. Drugs of 
this class, such as tirofiban and eptifibatide, are administered 
after percutaneous transluminal coronary angioplasty in an 
attempt to maintain arterial patency. These drugs have been 
engineered to bind tightly to a specific sequence of amino 
acids (arginine-glycine-aspartic acid) on GPIIb/IIIa to block 
platelet activation. In doing so, slightly altered conforma-
tions occur in the glycoprotein complex to allow the binding 
of preexisting auto-antibodies, which would not have a target 
in the absence of the drug’s effect.17,18 Interestingly, although 
both tirofiban and eptifibatide achieve their pharmacologic 
presence through the same mechanism, the conformational 
changes they induce in GPIIb/IIIa appear to be different be-
cause antibodies capable of clearing platelets that have been 
treated with one of these drugs usually do not bind to plate-
lets treated with the other.19
 Another drug in common use to inactivate circulating 
platelets is abciximab. This is a chimeric monoclonal anti-
body, the murine portion of which is targeted to GPIIb/IIIa 
and blocks binding with fibrinogen. Some individuals have 
naturally occurring antibodies to the murine portion of the 
antibody, and administration of the drug can lead to rapid 
and profound thrombocytopenia as the anti-mouse antibody 
bound to platelets clears the drug-platelet complex.20 Other 
patients form such an antibody about a week after initial ex-
posure, and thrombocytopenia can develop at this time as 
well.
Identifying the Culprit
 How can the laboratory help identify the presence of a 
DDPA that might be causing the thrombocytopenia in this 
case? A review to ensure that other laboratory results and 
clinical information do not point toward a nondrug cause 
(ITP) always has to be considered, but the sudden oc-
currence of platelet autoantibodies in this situation would 
be very unusual. A situation that is indistinguishable from 
ITP (with autoantibody formation) can occur with and well 
beyond the time of administration of some drugs, including 
L-dopa, procainamide, and gold salts, among others, al-
though none of these appears in the history of this case.9 The 
patient’s lymphoma may have returned to crowd out normal 
hematopoietic marrow elements, but the time course would 
likely be much more gradual. No drugs have been adminis-
tered recently that would suppress marrow function, and the 
patient’s leukocyte response to the infection was appropriate. 
The story also does not fit the time course or situation for ei-
ther disseminated intravascular coagulation (as the patient’s 
infection appears to be resolving) or thrombotic thrombocy-
topenic purpura. The patient has not received a transfusion 
recently, so posttransfusion purpura is not a viable explana-
tion.
 DDPAs can also cause reduced responsiveness to platelet 
transfusions. Serial posttransfusion platelet counts may be of 
some assistance in distinguishing the effects of DDPAs and 
alloantibodies: although most patients with HLA- or platelet-
specific alloantibodies fail to show the expected posttransfu-
sion response in the first hour, patients with DDPAs often 
have the expected 1-hour corrected count increment (CCI) 
but accelerated removal thereafter such that a good initial re-
sponse is followed by a poor CCI when measured at 18 to 24 
hours after transfusion.
 Thus, on first blush, considering DDPAs as the cause of 
the thrombocytopenia in this case seems logical. Although a 
primary immune response to a drug may take several weeks 
to much longer, an anamnestic response can occur in a few 
days to a week, and preformed antibodies can cause throm-
bocytopenia within hours.10 Given one’s multiple exposures 
to antibiotics throughout a lifetime and the potential for 
cross-reactivity of an antibody across a class of drugs, a rapid 
or anamnestic response may occur even without document-
ed (or recalled) prior exposure to an antibiotic.
What’s Going On?
 There are multiple pathogenic mechanisms that may lie 
behind drug-induced thrombocytopenia, and understand-
ing them can help explain the rationale for testing that may 
document the existence of DDPAs.
 Knowing that some drugs (including penicillins 
and cephalosporins) can bind covalently to proteins on 
cell membranes led to the theory of DDPA stimulation 
through hapten, or neoantigen, formation. The drug anti-
body would thus actually be targeting a drug-protein struc-
ture on the surface of cells, including RBCs or platelets.11 
However, this is not the mechanism that explains the actions 
of most DDPAs.
 Another model that has been advanced is that of antigen-
antibody complex formation. Here, the antibody is directed 
against the soluble form of the drug (or one of its metabolites), 
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via an enzyme immunoassay; the DDPA is thus detected by 
conversion of a substrate to a colored product. Because stan-
dardized kits are not available in the United States for such 
testing, referral of specimens to a reference laboratory usual-
ly is required. The resulting turnaround time renders the in-
formation useful only in retrospect usually, because clinical 
decisions about drug discontinuation often have to be made 
in a much shorter time frame.
 A commonly used approach for the detection of HLA- 
and platelet-specific antibodies can be adapted for the detec-
tion of drug antibodies. The solid-phase red cell adherence 
assay (SPRCA) technique can be adapted to detect DDPAs 
stimulated by a wide variety of drug classes.23,24 This tech-
nique can be learned by any skilled technologist and applied 
to yield clinically useful results in just a couple of hours, re-
moving the guesswork from changing a patient’s drug regi-
men. Validating such an assay should include comparison of 
results with a laboratory having an established reputation in 
the field. Performance of the technique is aided by close co-
operation with the hospital pharmacy in acquiring the need-
ed “reagent” drug supply and choosing the appropriate drug 
concentration to use in the system. Any assay for DDPAs 
will be hampered, of course, by the lack of ability to include 
drug metabolites in the test system (as these may, in some 
cases, be the chemicals that are the true culprits14) and by 
aqueous solubility limitations. If the patient also happens to 
be alloimmunized to HLA- or platelet-specific determinants, 
performance of this assay will require use of reagent platelets 
that lack the corresponding epitopes. This assay offers a nice 
complement to a laboratory’s ability to identify antibodies 
causing heparin-induced thrombocytopenia through a solid-
phase anti-platelet factor 4 (anti-PF4/heparin) enzyme im-
munoassay.25
 In cases in which the drug has caused a perturbation of 
the immune system and the generation of a true autoanti-
body, laboratory testing will be unable to identify the culprit 
drug because the autoantibody will bind with all platelets. 
Such antibodies usually target a structure in the GPIIb/IIIa 
complex and are indistinguishable from the autoantibod-
ies that arise in ITP. Further complicating assessment (and 
treatment) is the recognition that these autoantibodies may 
persist long after discontinuation of the drug. Recognition of 
the exact nature of the situation thus depends on identify-
ing one of the drugs known to cause this kind of problem on 
the patient’s medication list and demonstration of an ITP-
like autoantibody (not dependent on the presence of drug) by 
flow cytometry or SPRCA.
What Then?
 If the drug that caused the thrombocytopenia as a result 
of a DDPA can be identified and removed from the patient’s 
regimen, an increase in the platelet count should be seen rel-
atively quickly. The longer the serum half-life of the drug, of 
course, the slower will be the recovery. The patient’s platelet 
count usually will begin to recover (or responses to platelet 
should be performed first. Reviewing lists of most commonly 
encountered causative agents of DDPAs would be a good 
next step, as many clinicians may not be aware of the sub-
stantial frequency with which some drugs induce DDPAs and 
thrombocytopenia. Certainly heparin should be on this list,6 
but the list extends far beyond this and includes some often-
implicated antibiotics (Table 2).
 There are several types of assays that are applied by ref-
erence laboratories to detect DDPAs.3,21,22 Flow cytometry is 
commonly used to detect an increase in binding of IgG to 
platelets after incubation with drug and the patient’s serum. 
(The order of addition—incubation of platelet with drug fol-
lowed by addition of serum versus the incubation of drug with 
serum followed by addition of this mixture to platelets—may 
depend on the pathophysiologic mechanism at work, and the 
alternative can be tried if the initial approach is not positive, 
because variations are seen among patients and certainly 
among drugs.) A similar approach of incubating normal 
platelets with drug and patient serum can be followed with 
detection of IgG bound to platelets using goat anti-human 
IgG conjugated to alkaline phosphatase to detect the DDPA 
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*This listing includes drugs reported in the literature as causes of im-
mune drug-induced thrombocytopenia or encountered in the authors’ 
experience.10 The reader is referred to a Web site provided by Dr. 
James George, University of Oklahoma, for an updated, well-
characterized compendium of reports of drugs inducing thrombocy-
topenia: www.ouhsc.edu/platelets. Consideration should also be given 
to thrombocytopenia arising after ingestion of folk or herbal remedies.
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transfusions return to normal) within 2 to 5 days. Although 
antibodies to drugs can decline or disappear despite contin-
ued administration,26 discontinuation, especially in profound 
thrombocytopenia, would usually be advised, followed by 
avoidance of the drug in the future for fear of provoking an 
even stronger anamnestic response.10 Substitution of a drug 
in the same class as the offending drug usually does not result 
in thrombocytopenia owing to cross-reactivity of the DDPA 
despite chemical similarities of the pharmacologic agents.27 
However, caution and close observation may be advisable.
 While the issue of DDPAs is being investigated, it may 
also be worthwhile to examine the patient’s RBCs. In the case 
presented above, is the new anemia related to the DDPA, to 
hydration status, or to a marrow-based problem? RBCs can 
be subject to accelerated removal from circulation through 
some of the same mechanisms as platelets, and, because of 
the different surface proteins of RBCs, the prominence of 
anemia versus thrombocytopenia may vary between situa-
tions. Nevertheless, recognition that drug-induced hemo-
lysis is occurring or may occur could provide useful clinical 
information and impetus for a change in the patient’s drug 
regimen. For example, in one series (preliminarily reported 
in Leach et al.28), 10 of 17 selected patients with a DDPA that 
had been identified by SPRCA also had a positive direct an-
tiglobulin test; the eluates from all 10 patients failed to react 
in an RBC antibody panel, but 7 of these contained the same 
DDPA that had been identified in the patient’s serum and re-
acted in a DDPA SPRCA.
 In conclusion, the very real possibility that a drug is caus-
ing a patient’s thrombocytopenia deserves investigation and, 
if substantiated, concerted action. Although not all situations 
will be able to be resolved through laboratory testing, there 
is clearly assistance the laboratory can provide to help guide 
possible changes in the patient’s drug regimen.
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